Lumigan in Argentina: prescription, pharmacy and pricing
Lumigan (Bimatoprost) is available in Argentina under the regulatory framework of ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lumigan 0.01%, 0.03%.
- Regulator
- ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- Currency
- ARS
- Active ingredients
- Bimatoprost
- Available dosages
- 0.01%, 0.03%
Prescription status in Argentina
In Argentina, prescription-only medications are dispensed against signed and stamped prescriptions; certain controlled medications use special triplicate forms. Many medications are otherwise available with pharmacist-only oversight. Lumigan contains the active ingredient Bimatoprost, in the Eye Care and Ophthalmic Treatments class, and its classification in Argentina follows the standard rules of ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica).
Pharmacy dispensing
Farmacias argentinas operate as independent businesses or small chains; the pharmacist is a respected first-line consultant. Coverage by social security funds (obra social) often subsidises chronic medications. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lumigan at the available strengths (0.01%, 0.03%).
Online and tele-prescribing access
Online sale of prescription medication is regulated by ANMAT and largely limited to authorised pharmacy chains; informal online sources are common but not legal channels. Buying Lumigan from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Bimatoprost.
When Lumigan is prescribed
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Pricing and availability in ARS
Retail pricing in Argentina depends on the strength (0.01%, 0.03%), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lumigan in Argentina? ▾
In Argentina, prescription-only medications are dispensed against signed and stamped prescriptions; certain controlled medications use special triplicate forms. Many medications are otherwise available with pharmacist-only oversight. In practice, Lumigan follows the status of its active ingredient Bimatoprost in the regulatory system of ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica).
Is generic Lumigan available in Argentina? ▾
Authorised generics of Bimatoprost are typically available in Argentina at a lower cost than branded Lumigan, with bioequivalence required by ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lumigan cost in ARS? ▾
Prices in ARS vary by pharmacy and by strength (0.01%, 0.03%). Authorised generics of Bimatoprost are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Argentina.
Lumigan in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.